Research programme: hepatitis C virus polymerase inhibitors - B&C Pharma/XTLAlternative Names: BC 2329; HCV-SM
Latest Information Update: 11 Jul 2007
At a glance
- Originator B&C Pharma
- Class Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 28 Dec 2005 This programme is still in active development
- 19 Jan 2004 Data presented at the Frontiers in drug development for Viral Hepatitis - Hep DART 2003 (Hep DART-2003) have been added to the adverse events, pharmacokinetics and pharmacodynamics sections
- 07 Jul 2003 A potential drug candidate, HepeXTM-C SM1, has been identified for further development